Yazen Secures €6.5 Million Credit Facility from HSBC Innovation Banking
Secured financing from HSBC Innovation Banking supports accelerated expansion and optimises funding mix
Yazen, the leading digital obesity clinic offering medically supervised weight loss through a combination of lifestyle interventions and modern medications, has secured a €6.5 million credit facility from HSBC Innovation Banking. The financing marks a significant milestone for the company as it accelerates its growth and reinforces its financial flexibility.
2025 marked another record-breaking year for the digital healthcare provider Yazen. Revenue increased from approximately €15.7 million to nearly €29.4 million - a growth of 87 percent. At the same time, gross profit doubled to around €16.5 million.
The new financing will be used to support Yazen’s continued expansion across existing and new markets, optimise its funding mix, and strengthen its balance sheet while preserving shareholder value.
“Our collaboration with HSBC Innovation Banking enables us to accelerate key strategic initiatives,” said Fredrik Meurling, CEO of Yazen. “We have already been able to significantly scale up our marketing activities in January - a critical month for patient acquisition. This facility provides the flexibility to act faster and more forcefully in moments that matter.”
Yazen’s treatment model combines a digital care platform with a multidisciplinary team of doctors, health coaches, dietitians, psychologists, and physiotherapists. The approach integrates modern GLP-1 medications such as Ozempic and Wegovy with continuous, personalised lifestyle support - a model that has helped over 53,000 patients lose more than 640 metric tonnes in total.
Paula Burke, Director, Life Sciences and Healthcare, HSBC Innovation Banking UK: “HSBC Innovation Banking is delighted to support Yazen as it enters its next phase of growth. This financing underscores our commitment to partnering with innovative healthcare companies that can deliver meaningful impact, and we’re proud to partner with the experienced team at Yazen as they expand their differentiated weight-loss solutions to new markets.”
Yazen’s mission is to make high-quality obesity care accessible, effective, and dignified - helping patients reclaim their health and reduce the societal burden of chronic weight-related conditions.
For more information, please contact:
Fredrik Pallin, VP Public Relations Yazen: fredrik.pallin@yazen.com, +46 708 114 115
** ENDS **
About Yazen
Yazen is a digital healthcare provider specialised in the treatment of obesity - a chronic disease that requires long-term care. We are currently active in seven markets: Sweden, Norway, Denmark, the Netherlands, the United Kingdom, Germany, and Spain. Our team consists of 290 employees, of which 220 work in clinical care - including 130 licensed physicians.
Our unique model combines modern medications, continuous digital care, and support from a full healthcare team of your own physician and support from a full healthcare team of a health coach, dietitian, psychologist and physiotherapist. Research shows that this holistic approach leads to better and more sustainable outcomes than medication alone.
Yazen has been named ‘Weight Loss Treatment of the Year in Europe 2025’ by the international journal Healthcare Business Review, and also ranked as the second fastest-growing startup in Europe by The Sifted 250 Leaderboard.
Learn more at www.yazen.com
About HSBC Innovation Banking
HSBC Innovation Banking provides commercial banking services, expertise and insights to the technology, life science and healthcare, private equity and venture capital industries. HSBC Innovation Banking is a subsidiary of HSBC Group, benefiting from its stability, strong credit rating and international reach to help fuel its growth.
HSBC Holdings plc, the parent company of HSBC, is headquartered in London. HSBC serves customers worldwide from offices in 57 countries and territories. With assets of US$3,234bn at 30 September 2025, HSBC is one of the world’s largest banking and financial services organisations.
© 2026 HSBC Innovation Bank Limited. All rights reserved. HSBC Innovation Bank Limited (trading as HSBC Innovation Banking) is not licensed to undertake banking business or to undertake any other regulated activity in Denmark or Sweden. HSBC Innovation Bank Limited (trading as HSBC Innovation Banking) is registered in England and Wales at Alphabeta, 14-18 Finsbury Square, London EC2A 1BR, UK (Company Number 12546585). HSBC Innovation Bank Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and Prudential Regulation Authority (Firm Reference Number 543146). HSBC Innovation Bank Limited is part of the HSBC Group. HSBC Innovation Bank Limited is committed to making its website and related documents accessible to everyone. Learn more on www.hsbcinnovationbanking.com/accessibility
